Urinary Tract Infection Caused By Enterococcus Spp: Risk Factors And Mortality. An Observational Study.

Elisa Alvarez-Artero  
CAUPA

Amaia Campo Nuñez  
CAUPA

Inmaculada Garcia Garcia  
CAUSA

Moises Garcia Bravo  
CAUPA

Olia Cores  
CAUSA

Inmaculada Galindo Perez  
CAUPA

Jose Pendones  
CAUSA

Amparo Lopez Bernus  
CAUSA

Moncef Belhassen-Garcia  
mbelhassen@hotmail.com  
Hospital Universitario de Salamanca  
https://orcid.org/0000-0002-2230-1256

Javier Pardo Lleidas  
Marques de Valdecilla

Research article

Keywords: Urinary tract infection, Enterococcus spp., Mortality, Bacteremia, Immunosuppression

DOI: https://doi.org/10.21203/rs.3.rs-32100/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background

Urinary tract infections (UTIs) are frequently caused by Enterococcus spp. We aim to define the risk factors involved in UTIs caused by Enterococcus. Determine the overall mortality and predictive risk factors.

Methods

A retrospective in-patients study was conducted with bacteriemic UTIs caused by Enterococcus spp. We compared bacteriemic UTIs caused by Enterococcus spp. vs. a random sample of 100 in-patients with bacteriemic UTIs caused by others enterobacteria.

Results

We found 106 in-patients with UTIs caused by Enterococcus spp., 51 of whom had concomitant positive blood cultures. Distribution by species was: 83% E. faecalis and 17% E. faecium, with a Charlson comorbidity index of 5.9 ± 2.9. When we compared bacteriemic UTIs caused by Enterococcus spp. vs. bacteriemic UTIs caused by others enterobacteria we found the following independent predictors of bacteriemic UTI by Enterococcus: male sex with an OR of 6.1 (95%CI 2.3–16.1), uropathy with an OR of 4.1 (1.6–10.1), nosocomial infection with an OR of 3.8 (1.4–10.3), urinary cancer with an OR of 6.4 (1.3–30.3) and previous antimicrobial treatment with an OR of 18 (5.2–62.1). Overall, in-patient mortality was 16.5%, which was associated with a higher Sequential Organ Failure Assessment (SOFA) score (> 4), severe comorbidity such as immunosuppression, malignant hemopathy and nephrostomy, or Enterococcus faecium species and its pattern or resistance to ampicillin or vancomycin (p < 0.05). Appropriate empiric antibiotic therapy was not associated with a better prognosis (p > 0.05).

Conclusions

Enterococcus spp. is a frequent cause of complicated UTI by a profile of risk factors. High mortality secondary to a severe clinical setting and high comorbidity may be sufficient reasons for implementing empiric treatment of patients at risk, although we did not show a higher survival rate in patients with this treatment strategy.

Backgroud

The Enterococcus genus is included in the Enterococcaceae family, in which there are more than 30 recognized species, although Enterococcus faecalis, Enterococcus faecium and Enterococcus durans are the three main species that affect humans(1)
*E. fecalis* and *E. faecium* are rare causes of urinary tract infections (UTIs) in young women. Nevertheless, they are frequently involved in complicated infections. Thus, recent epidemiological studies have detected that these species are the second cause of complicated UTIs, followed by *Escherichia coli*, reaching 7–25% of the total number of cases of UTIs(2, 3).

Despite the high frequency of UTIs caused by *Enterococcus* spp., there is a low rate of bacteremia associated with infection(2, 4). Moreover, in mixed UTIs, where other uropathogens are involved, isolation of *Enterococcus* spp. is considered a commensal pathogen and is usually not treated (5). On the one hand, Enterococci are tolerant or intrinsically resistant (particularly *E. faecium*) to several antimicrobials, such as broad spectrum penicillins, cephalosporins and carbapenems, that are typically used in complicated UTIs.

Moreover, glycopeptides, linezolid or other antibiotics active against gram-positive bacteria are usually not included in empiric recommendations of guidelines for the treatment of urinary tract infections. In recent guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) about the management of UTIs and The European Association of Urology (EAU) Urological Infections Guidelines Panel, the empiric treatment of the enterococcus species has been suggested for patients with classic risk factors for this infection(6–8).

Although risk factors for overall bacteremia by *Enterococcus* spp. have been defined in the literature, the risk factors for UTI have not been well defined, and the consequences of a delay in optimal treatment have also not been well demonstrated.

Thus, the aim of this work was to describe the UTIs caused by *Enterococcus* spp., identifying the risk factors involved in hospitalized patients, and the overall mortality and consequences of non-optimal empiric treatment.

**Methods**

**Patients**

First a retrospective, observational study during the years 2012–2017 was carried out in two centers of Castilla y León: Complejo Asistencial de Palencia (CAUPA) and Complejo Asistencial Universitario de Salamanca (CAUSA). We reviewed the records of in-patients with a diagnosis of urinary tract infection caused by *Enterococcus* spp from January 2012 to December 2017 as shows in Fig. 1. We included to patients admitted to any services at these centers who needed hospitalization with clinical manifestations compatible with urine tract infection (UTI). UTI is considered if the patient presents cystic syndrome (dysuria, frequency and/or nocturia) or acute pyelonephritis (if there was pain in the renal fossa, fever > 37.7°C, involvement of the parenchyma during imaging techniques or criteria presented for systemic inflammatory response syndrome (SIRS) ); or ancient patients (> 65 years) with confusional syndrome and fever > 37.7 without other infectious foci. Sepsis or septic shock was considered if the recommendations of the Third International Consensus Definitions for Sepsis and Septic Shock were
The Sequential Organ Failure Assessment (SOFA) and Pitt Bacteremia Score (PBS) were systematically collected when samples were taken. The PBS was calculated for each patient at baseline when samples were taken(10). Hypotension, mechanical ventilation, mental status, and maximum temperature parameters of the PBS were measured for the baseline date. We used the Friedman criteria for the classification of UTIs as nosocomial, associated with care or community-acquired(11).

Microbiological criteria for urinary infection caused by Enterococcus were confirmed by isolation of *E. faecalis* or *E. faecium* in urine cultures ($10^5$ CFU/ml). We selected as cases, those patients with concomitant urine and blood cultures, and a random sample of patients with UTIs caused by Enterococcus with blood culture done without bacteremia.

Second, we compared bacteremic UTIs caused by *Enterococcus* spp. vs. a random sample of 100 inpatients with bacteremic UTI caused by other enterobacteria. We used the same clinical and microbiological diagnostic criteria for enterobacteria as for *Enterococcus* spp.

The exclusion criteria for the study were as follows: i) patients who presented other concomitant infectious foci and ii) patients who fulfilled the definition of asymptomatic bacteriuria. All patients included in the study participated in a protocol that included the collection of demographics, epidemiological and clinical data. The empirical and directed antibiotic treatment and the carrying out of blood cultures and imaging studies were left to the clinician's discretion. The usual recommendations for taking samples according to the protocol were applied in the two centers. Urine specimens collected by clean catch were plated on agar blood (bioMérieux, Spain) and agar MacConkey (bioMérieux, Spain) using a 0.001-ml calibrated loop. Samples collected from indwelling catheters or transurethral catheterization were also plated on CLED agar (bioMérieux, Spain). All plates were incubated for 24 hours at 35–37 °C. A colony count of $10^5$ cfu/mL was considered positive. Identification and susceptibility were assessed with an automated MicroScan WalkAway system (Beckman Coulter, Spain). MIC was interpreted according to the cut-off points of the European Committee for Antimicrobial Susceptibility Testing (EUCAST). Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was used for the identification of species of Enterococcus when the results of biochemical methods were doubtful.

Finally, the presence of endocarditis was analyzed collecting those patients with bacteremia in which echocardiography was performed.

**Data analysis**

The results obtained were expressed as the mean ± Standard Deviation (SD) and percentage. The risk factors were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). The $X^2$ test was used to evaluate the risk factors for urinary tract infections (UTIs) caused by Enterococcus. Moreover, we used the $X^2$ test for the analyses of mortality. A multivariate analysis was carried out, introducing only the variables with statistical significance ($p < 0.05$) in the univariate analysis. Receiver operating characteristic (ROC) curves were performed to evaluate and compare the validity of the PBS and SOFA as
predictors of mortality. Binary logistic regression was carried out by introducing only the variables that were significant in the bivariant analysis. The odds ratio with 95% CI was assessed in all significant variables. Data analysis was performed using SPSS 25.0 (Statistical Package for the Social Sciences).

Results

In this study, we included one hundred and six patients with UTIs caused by Enterococcus spp. The main characteristics of the patients are shown in Table 1. Seventy-three (68.9%) patients were male, with an average age of 73.8 ± 19 years and an average Charlson comorbidity index of 5.9 ± 2.9. A total of 87.6% of the patients had a Charlson index ≥ 3. Thirty-three (31.1%) patients had community-acquired UTIs, 23 (21.7%) had healthcare-associated UTIs, and 50 (47.2%) had hospital-acquired UTIs. Of the patients with UTIs caused by Enterococcus spp, 51 (48.1%) had positive urine and blood cultures. E. faecalis was the most frequently detected isolation in 88 of the patients (83%), followed by E. faecium in 18 (17%) patients. A total of 9 (10.2%) patients also had other simultaneous isolations. Patients demonstrated an average SOFA score of 2.1±2.2, and 15% demonstrated a SOFA score > 5. Among the patients, 31 (31%) had sepsis, and 7 (6.6%) had septic shock. Twenty-one (24%) patients with UTIs caused by Enterococcus spp. were resistant to ampicillin, and 5.3% were resistant to vancomycin. Moreover, one-third of patients with UTIs caused by E. faecium were resistant to both types of antimicrobials. The risk factors associated with resistance to ampicillin were hematological neoplasia [OR 5.8 (95%CI 1.2–27.4) p < 0.05], febrile neutropenia [OR 8.5 (IC 95 1.4–49) p < 0.05], organ solid transplantation [OR 3.3 (IC 95 0.8–13.2) p > 0.05] and immunosuppression treatment [OR 3.2 (IC 95 0.9–10.6) p > 0.05]. The random sample of 100 in-patients with bacteriemic UTI of others enterobacteria was 73 Eschericha coli, 9 Proteus spp., 6 Klebsiella spp., 3 Enterobacter spp., 3 Morganella spp., 3 Providencia spp., 3 Citrobacter spp. The results of the univariable analysis for bacteriemic UTIs caused by enterococcus vs bacteriemic UTIs caused by enterobacteria are shown in Table 2.
Table 1  
Characteristics of patients with UTI caused by *Enterococcus* spp. included in the study.

| **Enterococcus spp. Total, N (%) 106** |
|----------------------------------------|
| Age ± SD; years                        | 73.8 ± 19.0 |
| Gender male n (%)                      | 68 (64.2)   |
| **Acquisition n (%)**                  |             |
| Hospital                               | 50 (47.2)   |
| Community                              | 33 (31.1)   |
| Health care                            | 23 (21.6)   |
| **Clinical setting n (%)**             |             |
| Sepsis                                 | 34 (32.1)   |
| Pyelonephritis                         | 18 (20.5)   |
| Shock                                  | 7 (6.7)     |
| Cystitis                               | 2 (2.3)     |
| **SOFA score ± SD**                    | 2.1 ± 2.2   |
| **Charlson index comorbidity ± SD**    | 5.9 ± 2.9   |
| **Risk factors n (%)**                 |             |
| Uropathy                               | 68 (64.2)   |
| Antibiotic 6 month ago                 | 55 (67.1)   |
| Bladder catheter                       | 19 (19.2)   |
| Diabetes                               | 27 (25.7)   |
| Urinary cancer                         | 18 (20.2)   |
| Immunosuppression                      | 17 (18.9)   |
| Nephrostomy                            | 12 (13.3)   |
| Hemopathy malign                       | 9 (10.1)    |
| Double J stent                         | 8 (9.5)     |
| Solid organ transplantation            | 7 (8)       |
| Neutropenia (< 500/mm³)                | 7 (8)       |
| **Enterococcus spp. n (%)**            |             |
| Enterococcus spp. Total, N (%) 106 |
|----------------------------------|
| E. faecalis                      88 (83) |
| E. faecium                      18 (17) |
| Another coinfection             9 (10.2) |
| Blood culture positive          51 (48.1) |

**Antimicrobial resistance n (%)**

|                | n (%)   |
|----------------|---------|
| Ampicillin     | 21 (24.4) |
| Vancomycin     | 5 (5.3) |
| Endocarditis association | 3 (2.8) |
| In-mortality n (%) | 17 (16.5) |
|                           | Enterococcus spp bacteriemic UTI | Enterobacteria bacteriemic UTI | OR (CI 95%) | p   |
|---------------------------|----------------------------------|-------------------------------|------------|-----|
| Male                      | 40 (78.4)                        | 37 (37.1)                     | 6.1 (2.3–16.1) | 0.000 |
| Diabetes                  | 14 (27.5)                        | 29 (28.6)                     | 0.9 (0.3–2.4)  | 0.909 |
| Uropathy (not renal failure) | 36 (70.6)                      | 37 (37.1)                     | 4.1 (1.6–10.1) | 0.002 |
| Nosocomial infection       | 25 (49)                          | 20 (20)                       | 3.8 (1.4–10.3) | 0.006 |
| Bladder catheter          | 9 (17.6)                         | 6 (6.0)                       | 3.5 (0.7–17.4) | 0.104 |
| Double J stent            | 7 (15.9)                         | 0 (0)                         | NC          | -    |
| Nephrostomy               | 9 (18)                           | 0 (0)                         | NC          | -    |
| Immunosuppression         | 10 (20)                          | 6 (6.0)                       | 4.1 (0.8–20.1) | 0.063 |
| Urinary cancer            | 14 (28)                          | 6 (6.0)                       | 6.4 (1.3–30.3) | 0.010 |
| Hemopathy malign          | 4 (8)                            | 0 (0)                         | NC          | -    |
| Neutropenia (< 500/mm³)   | 3 (6.7)                          | 0 (0)                         | NC          | -    |
| Solid organ transplantation| 6 (12)                           | 3 (3.0)                       | 4.6 (0.5–40.3) | 0.131 |
| Antibiotic 6 month ago    | 30 (78.9)                        | 17 (17.0)                     | 18 (5.2–62.1) | 0.000 |

When we compared bacteriemic UTIs caused by *Enterococcus* spp. vs. bacteriemic UTIs caused by others enterobacteria we found the following independent predictors of bacteriemic UTI by *Enterococcus*: male sex with an OR of 6.1 (95%CI 2.3–16.1), uropathy with an OR of 4.1 (1.6–10.1), nosocomial infection with an OR of 3.8 (1.4–10.3), urinary cancer with an OR of 6.4 (1.3–30.3) and previous antimicrobial treatment with an OR of 18 (5.2–62.1).

We also studied the variables associated with UTIs with bacteremia. Urinary cancer [OR 3.4 (95%CI 1–11.3) p < 0.05] and solid organ transplantation [OR 9.7 (95%CI 1.1–79.8) p < 0.05] were the only risk factors associated with bacteremia caused by enterococcus.
The overall in-patient mortality for UTIs caused by *Enterococcus* spp. was 17(16,5%). The predictive risk factors for mortality are shown in Table 3: Malignant hemopathy [OR 4.8 (95%CI 1.1–20.7) p < 0.05], immunosuppression treatment [OR 4.1 (95%CI 1.2–14.1) p < 0.05], nephrostomy [OR 4.6 (95%CI 1.2–17.4) p < 0.05], ampicillin resistance [OR 8.7 (95%CI 2.5–29.8) p < 0.05], and vancomycin resistance [OR 9.3 (95%CI 1.4–62) p < 0.05]. Moreover, a SOFA score ≥ 2 was also associated with higher mortality, but these differences did not reach a significant level (OR 4.1 (0.8–21.5) p < 0.05).

### Table 3

| Variables                                      | Mortality (%) | OR (CI 95%) | p     |
|-----------------------------------------------|---------------|-------------|-------|
| Nephrostomy vs no-nephrostomy                 | 41 vs 13      | 4.6 (1.2–17.4) | 0.030 |
| Immunosuppression vs non immunosuppresion     | 37 vs 12      | 4.1 (1.2–14.1) | 0.028 |
| Hemopathy malign vs no-hemopathy              | 44 vs 14      | 4.8 (1.1–20.7) | 0.046 |
| Ampicillin resistant vs ampicilin sensible     | 47 vs 9       | 8.7 (2.5–29.8) | 0.001 |
| Vancomycin resistant vs vancomycin sensible    | 60 vs 13      | 9.3 (1.4–62)  | 0.029 |
| SOFA score 0–3 vs > 4 p                       | 10 vs 35      | 0.2 (0.1–0.9)  | 0.026 |
| *E. fecalis vs E. faecium*                    | 10 vs 50      | 0.1 (0.1–0.3)  | 0.0001|

Among patients with bacteremia, the SOFA score was a better predictor of mortality than the PBS (AUC-ROC 0.8 vs 0.5), as shown in Fig. 2.

We did not detect an association between bacteremia and mortality (p > 0.05). A total of 49.4% of patients with UTIs caused by *Enterococcus* spp. achieved correct, empiric antibiotic therapy according to the final antibiogram, although we did not detect a lower mortality rate in this group of patients (p < 0.05).

**Discussion**

Enterococci species are part of the healthy human gut microbiota(12) and sometimes can also colonize in the urinary tract, causing different clinical settings from asymptomatic bacteriuria (AB) to UTIs. Bacteriuria caused by enterococci has a deleterious effect on the urinary tract, which promotes innate immune suppression and increases the risk of infection by other uropathogens(13), suggesting that the treatment of AB can be successful in terms of the prevention of the recurrence of urinary tract infection. Nevertheless, paradoxically, it has been shown that antibiotic treatment of AB caused by *Enterococcus*, in patients with recurrent infection, increases the risk for recurrent urinary infection by other uropathogens(14). Regarding UTIs, *Enterococcus* spp. is the cause of cystitis, prostatitis and epididymitis(1). Experimental studies in mice have shown that enterococci can also affect the higher urinary tract, thus causing pyelonephritis(15), which is one of the most frequent pathogens involved in
complicated UTIs. In a review, enterococci was the cause in 7–25% of patients with severe urinary sepsis and UTIs(3). Despite these data, pyelonephritis caused by *Enterococcus* spp. is not usually associated with bacteremia(2, 4).

In this sense, empiric treatment against enterococci is not included in guidelines of UTIs management or is reserved only for patients at risk (6–8). Thus, the first aim of this work was to determine the risk factors associated with UTIs caused by enterococci. Although there are several studies that have analyzed the risk factors for bacteremia, there have been few studies that have focused on urinary infections and how these risk factors affect infection. Therefore, we reviewed the records from more than one hundred inpatient cases from different hospitals in Castilla y Leon (region of northwestern Spain) with a diagnosis of UTIs caused by Enterococcus, half of whom with positive blood cultures and the rest with negative blood cultures. In our cohort of patients, the main species that was detected was *E. faecalis*, whereas only fifteen percent of cases were due to *E. faecium*. This distribution, with a predominance of *E. faecalis*, also have been found in both a European(15) and North-American series of complicated UTIs cases(16).

Regarding demographic characteristics, male sex has been associated with *Enterococcus* spp. Thus, in a cohort of 700 patients with bacteremia, which included more than 180 patients with a urinary focus, there were twice as many males as females(15). Our results also support a predominance for male sex in complicated UTI cases, with or without bacteremia. In our work, nearly half of the cases of UTI caused by Enterococcus were acquired in a hospital. In a previous series of enterococcus infections, other authors have shown similar results(15) and have supported the fact that *Enterococcus* spp. must be considered, similar to *Pseudomonas aeruginosa*, especially in cases of nosocomial UTIs. *Enterococcus* spp. are frequently associated with biofilms of both blood and urinary catheters. In a recent study, patients with an indwelling catheter had twice the risk for *Enterococcus* spp. than other patients with community-acquired UTIs(17). In our cohort, the patients frequently had bladder, nephrostomy or double J catheters. It is possible, as is the case in other works, that the presence of a nephrostomy catheter is specifically involved in *Enterococcus* spp. infection(18).

The population in this study had a high comorbidity Charlson index. Among the different comorbidities demonstrated by the patients, the most important were urinary disorders or severe systemic diseases. Among urological diseases, urological cancer has been described as a risk factor for Enterococcus UTIs(19, 20). It is possible, as is the case in bacteremia associated with colorectal cancer(20), that lesions due to urinary epithelial colonization can be one of the most important predictive risk for urinary infections caused by Enterococcus.

*Enterococcus* species are considered by many authors an opportunistic pathogen(21), and factors such as immunosuppression, neutropenia or hemopathy are frequently detected as risk factors for bacteremia(16). The results of our work suggest that in this epidemiological setting, Enterococcus can be considered one of the most probable causes of UTI.

Finally, another risk factor detected in our work was previous antibiotic treatment. This finding is in accordance with other works in which patients treated with ceftriaxone were associated with an increased
risk for reinfection by *Enterococcus* spp(22). The fact that more than one-half of our patients had been treated in the previous month with 3rd -generation cephalosporins may explain these results.

Another aim of this study was to evaluate the variables associated with bacteremia. Although there are several studies that have analyzed bacteremia caused by enterococcus and its risk factors, they included different types of infections, and the results were not focused on UTIs(16, 20). In our study, we selected only patients with a clinical setting of UTIs and an isolation of enterococcus in urine culture, and we compared the risk factors in the two groups with and without bacteremia. Our results are consistent with other findings, and we showed that neutropenia, solid organ transplant, bone medullary transplant, and immunosuppression were also risk factors for bacteremia in patients with tract urinary infection caused by *Enterococcus* spp.(16, 20). These are the same classic risk factors in patients with bacteremia, regardless of other origins(4). Moreover, we detected that urinary cancer was associated with bacteremia in patients with UTIs. In a recent study, urological cancer was also associated with bacteremia(20). These results support that regardless of *E. faecalis* and *E. faecium* colonizing urinary tract infections, it is difficult for these pathogens to cross the urinary epithelium when innate immunity is preserved, but when it exists, rupture of the epithelial barrier can result in bacteremia.

Another objective of this work was to study the mortality and morbidity following UTIs caused by Enterococcus. The mortality rates seen with this infection in our study were higher than those in other series of in-patients with UTIs(23, 24) and were similar to those shown by Billinton *et al.*(16) in a subgroup of patients with urosepsis caused by Enterococcus. In our study, mortality was not different between patients with or without bacteremia. Factors that depend on the clinical setting, such as a high SOFA score and severe comorbidity (such as malignant hemopathy and immunosuppression), and factors that depend on the species involved (*E. faecium* vs *E. faecalis* or its pattern of resistance to ampicillin and vancomycin) were the only factors associated with high mortality. Similar data have been reported by other authors regarding bacteremia(15). We did not detect a lower mortality rate for patients with correct empiric treatment for *Enterococcus* spp. This result could be due to the small number of patients included in the study and to the heterogenicity in the empirical treatments performed. However, because our study was retrospective, it is also possible that there was a selection bias, so patients with optimal empirical treatment according to the last antibiogram could also be the most critical.

Finally, we evaluated infectious endocarditis, a frequent morbidity detected in patients with bacteremia caused by *Enterococcus* spp. In a Danish cohort, 6% of patients with nosocomial infections and 25% of patients with community-acquired infections had infectious endocarditis. In our study, we found endocarditis in 5.8% of patients with UTIs and bacteremia with a urinary origin (2.8% of the total patients included in the study). These data support that in patients with bacteremia and a urinary focus, echocardiography must be performed to diagnose this severe complication(15).

We believe that our work can help to better define a group of patients with urinary infection that have a high mortality, thus requiring a differentiated antimicrobial treatment from the one included in the current guidelines. Nevertheless, we also recognize that our work has some limitations. It was a retrospective
study of in-patients, with a relatively low number of patients and with selection bias, so risk factors or mortality may not be similar in other populations of patients.

**Conclusion**

Enterococcus is one of the most frequent causes of UTIs complicated by a profile of risk factors, in which male sex, a high Charlson index, urinary catheter, previous antibiotic treatment, urological cancer or several types of immunosuppression are the main predictive factors. These last two factors are also risk factors for bacteremia. High mortality secondary to a severe clinical setting and high comorbidity may be sufficient reasons for implementing empiric treatment of patients at risk, although we did not show a higher survival rate in patients with this treatment strategy.

**Abbreviations**

1. Urinary tract infections (UTIs)
2. Sequential Organ Failure Assessment (SOFA)
3. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)
4. The European Association of Urology (EAU)
5. Complejo Asistencial de Palencia (CAUPA)
6. Complejo Asistencial Universitario de Salamanca (CAUSA).
7. Systemic inflammatory response syndrome (SIRS)
8. Pitt bacteremia score (PBS)
9. CFU colony-forming unit
10. MIC minimum inhibitory concentration
11. European Committee for Antimicrobial Susceptibility Testing (EUCAST)
12. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)
13. Standard Deviation (SD)
14. Odds ratios (ORs)
15. Confidence intervals (CIs).
16. Receiver operating characteristic (ROC)
17. SPSS 25.0 (*Statistical Package for the Social Sciences*).
18. Catheter urinary tract infection (CAUTI)

**Declarations**

**Ethics approval and consent to participate**
This work was performed in accordance with the ethical standards laid down in the Declaration of Helsinki as revised in 2013. The study protocol was approved by the Ethical Review Board of Complejo Asistencial Universitario de Salamanca (CAUSA, Salamanca Spain) with the assigned code PI78/06/2018. Since this was a retrospective observational study, our Institutional Review Board accepted to proceed to data compilation and analysis with no previous informed consent obtained from the participants. All clinical and epidemiological data were anonymized.

Consent to publish

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Funding

None declared.

Authors' contributions

1. EAA. Study design, Data collection, Data analysis, Writing
2. ACN. Data collection, Data analysis
3. IGG. Data collection, Data analysis
4. MGB. Data collection, Data analysis
5. OCC. Data collection, Data analysis
6. IGP. Data collection, Data analysis
7. JPU. Data collection, Data analysis
8. ALB. Data collection, Data analysis
9. MBG. Study design, Data collection, Data analysis, Writing
10. JPLL. Study design, Data collection, Data analysis, Writing

Acknowledgements
References

1. Gilmore MS, Clewell DB, Shankar N, Ness IF, Diep DB, Ike Y. Enterococcal Bacteriocins and Antimicrobial Proteins that Contribute to Niche Control. Boston: Massachusetts Eye and Ear Infirmary; 2014.

2. Artero E, Nuñez AC, Bravo MG, Calvo OC, Garcia MB, Lledias JP, et al. Infección urinaria en el anciano. Revista Clínica Española. Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI); 2019 Feb 13;:1–5.

3. Wang FY, Fang B, Qiang XH, Yu TO, Zhong JR, Cao J, et al. The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin α1 for Sepsis: A Systematic Review and Meta-Analysis. BioMed Research International. Hindawi; 2016 May 31;2016(2):1–8.

4. Artero A, Esparcia A, Eiros JM, Madrazo M, Alberola J, Nogueira JM. Effect of Bacteremia in Elderly Patients With Urinary Tract Infection. The American Journal of the Medical Sciences. Elsevier; 2016 Aug 6;:1–5.

5. Kline KA, Lewis AL. Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract. Microbiology Spectrum. 2016 Apr 1;4(2):1–31.

6. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases. 2011 Mar 1;52(5):e103–20.

7. De Cueto M, Aliaga L, Alós J-I, Canut A, Los-Arcos I, Martínez JA, et al. Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enfermedades infecciosas y microbiología clínica. SEGO; 2017 May 1;35(5):314–20.

8. Bonkat G, Pickard R, Bartoletti R, Association FBE. 2017. EAU guidelines on urological infections. uroweborg.

9. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb;23(8):801–10. 315(.

10. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteremia: a commentary. Int J Antimicrob Agents. 1999 Jan;11(1):7–12.

11. Health Care–Associated Bloodstream Infections in Adults. A Reason To Change the Accepted Definition of Community-Acquired Infections. 2002 Oct 31;:1–8.

12. Kao PHN, Kline KA. Dr. Jekyll and Mr. Hide: How Enterococcus faecalis Subverts the Host Immune Response to Cause Infection. Journal of Molecular Biology. Academic Press; 2019 Jul 26;431(16):2932–45.
13. Tien BYQ, Goh HMS, Chong KKL, Bhaduri-Tagore S, Holec S, Dress R, et al. Enterococcus faecalis Promotes Innate Immune Suppression and Polymicrobial Catheter-Associated Urinary Tract Infection. Freitag NE, editor. Infect Immun. 2017 Nov 17;85(12):225–44.

14. Cai T, Mazzoli S, Mondaini N, Meacci F, Nesi G, D’Elia C, et al. The Role of Asymptomatic Bacteriuria in Young Women With Recurrent Urinary Tract Infections: To Treat or Not to Treat? Clinical Infectious Diseases. 2012 Aug 21;55(6):771–7.

15. Pinholt M, Østergaard C, Arpi M, Bruun NE, Schønheyder HC, Gradel KO, et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006–2009: a population-based cohort study. Clin Microbiol Infect. 2014 Feb;20(2):145–51.

16. Billington EO, Phang SH, Gregson DB, Pitout JDD, Ross T, Church DL, et al. Incidence, Risk Factors, and Outcomes for Enterococcus spp. Blood Stream Infections: A Population-Based Study. International Journal of Infectious Diseases. International Society for Infectious Diseases; 2014 Sep 1;26:76–82.

17. Shrestha LB, Baral R, Khanal B. Comparative study of antimicrobial resistance and biofilm formation among Gram-positive uropathogens isolated from community-acquired urinary tract infections and catheter-associated urinary tract infections. IDR. 2019;12:957–63.

18. Lara-Isla A, Medina-Polo J, Alonso-Isa M, Benítez-Sala R, Sopeña-Sutil R, Justo-Quintas J, et al. Urinary Infections in Patients with Catheters in the Upper Urinary Tract: Microbiological Study. Urol Int. 2017 May 30;98(4):442–8.

19. Werntz RP, Martinez-Acevedo A, Amadi H, Kopp R, La Rochelle J, Koppie T, et al. Prophylactic antibiotics following radical cystectomy reduces urinary tract infections and readmission for sepsis from a urinary source. 12;. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2018 Jan. pp. 1–5.

20. Cabiltes I, Coghill S, Bowe SJ, Athan E. Enterococcal bacteraemia “Silent but deadly”: a population-based cohort study. Intern Med J. 2019 Jun;10;;imj.14396–24.

21. Goh HMS, Yong MHA, Chong KKL, Kline KA. Model systems for the study of Enterococcal colonization and infection. Virulence. Taylor & Francis; 2017 May 4;8(8):1525–62.

22. Magnussen CR, Cave J. Nosocomial enterococcal infections: association with use of third-generation cephalosporin antibiotics. Am J Infect Control. 1988 Dec;16(6):241–5.

23. van derStarre WE, Zunder SM, Vollaard AM, van Nieuwkoop C, Stalenhoef JE, Delfos NM, et al. Prognostic value of pro-adrenomedullin, procalcitonin and C-reactive protein in predicting outcome of febrile urinary tract infection. Clinical Microbiology Infection. 2014 Oct;20(10):1048–54.

24. Horcajada JP, Shaw E, Padilla B, Pintado V, Calbo E, Benito N, et al. Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clinical Microbiology and Infection. European Society of Clinical Infectious Diseases; 2014 Nov 21;19(10):962–8.
Figure 1

Participant profile.
Figure 2

Area under the ROC curve (AUC) of the SOFA score and PBS as predictors of mortality.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- STROBEchecklistv4combined.doc